Jonathan D Schoenfeld

List of Publications by Year
in descending order

103	4,738	136950 32	118850 62
papers	citations	h-index	g-index

106	106	106	7412
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Using immunotherapy to boost the abscopal effect. Nature Reviews Cancer, 2018, 18, 313-322.	28.4	844
2	Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma. JAMA Oncology, 2020, 6, 1563.	7.1	198
3	A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. OncoImmunology, 2015, 4, e1046028.	4.6	191
4	Frameshift events predict antiâ€“PD-1/L1 response in head and neck cancer. JCI Insight, 2018, 3, .	5.0	190
5	Is everything we eat associated with cancer? A systematic cookbook review. American Journal of Clinical Nutrition, 2013, 97, 127-134.	4.7	165
6	Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirusâ€“Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clinical Cancer Research, 2020, 26, 5140-5152.	7.0	163
7	Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 344-351.	0.8	143
8	Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1660-1667.	2.5	127
9	Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?. , 2021, 9, e002038.		124
10	The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. International Journal of Radiation Oncology Biology Physics, 2019, 103, 142-151.	0.8	118
11	Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncology, The, 2022, 23, 279-291.	10.7	118
12	Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell, 2022, 185, 2918-2935.e29.	28.9	113
13	Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. , 2019, 7, 89.		108
14	Salivary Gland Tumors Treated With Adjuvant Intensity-Modulated Radiotherapy With or Without Concurrent Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 308-314.	0.8	104
15	Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. , 2015, 3, 50.		84
16	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunology Research, 2016, 4, 679-687.	3.4	81
17	Hazards of Hazard Ratios â€” Deviations from Model Assumptions in Immunotherapy. New England Journal of Medicine, 2018, 378, 1158-1159.	27.0	79
18	PECAM-1 Affects GSK-3Î²-Mediated Î²-Catenin Phosphorylation and Degradation. American Journal of Pathology, 2006, 169, 314-324.	3.8	77

#	Article	IF	Citations
19	Active Immunotherapy Induces Antibody Responses That Target Tumor Angiogenesis. Cancer Research, 2010, 70, 10150-10160.	0.9	69
20	Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. , 2019, 7, 112.		69
21	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. British Journal of Cancer, 2016, 115, 252-260.	6.4	66
22	A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. International Journal of Radiation Oncology Biology Physics, 2021, 109, 134-144.	0.8	61
23	Merkel Cell Carcinoma: A Population Analysis on Survival. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1247-1257.	4.9	57
24	The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Womenâ€™s Cancer Center Multidisciplinary Guideline. Oncologist, 2017, 22, 343-350.	3.7	57
25	Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1259-1270.	0.8	54
26	Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era. Cancer, 2015, 121, 2594-2602.	4.1	53
27	Immunity in Head and Neck Cancer. Cancer Immunology Research, 2015, 3, 12-17.	3.4	53
28	Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2016, 22, 2939-2949.	7.0	51
29	Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiotherapy and Oncology, 2017, 124, 98-103.	0.6	51
30	A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 2470-2480.	7.0	51
31	Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2022, 28, 468-478.	7.0	45
32	A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. Clinical Breast Cancer, 2020, 20, 238-245.	2.4	44
33	PECAM-1 promotes Î²-catenin accumulation and stimulates endothelial cell proliferation. Biochemical and Biophysical Research Communications, 2003, 303, 212-218.	2.1	42
34	Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncology, 2017, 67, 61-69.	1.5	42
35	Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. Frontiers in Oncology, 2017, 7, 191.	2.8	42
36	Immunotherapy and radiotherapy for metastatic cancers. Annals of Palliative Medicine, 2019, 8, 312-325.	1.2	33

#	Article	IF	Citations
37	Oral immuneâ€related adverse events associated with PDâ€1 inhibitor therapy: A case series. Oral Diseases, 2020, 26, 325-333.	3.0	33
38	Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges. Frontiers in Oncology, 2020, 10, 608772.	2.8	30
39	Bioinformatic analysis of primary endothelial cell gene array data illustrated by the analysis of transcriptome changes in endothelial cells exposed to VEGF-A and PlGF. Angiogenesis, 2004, 7, 143-156.	7.2	29
40	Identification of the regions of PECAM-1 involved in Î²- and Î³-catenin associations. Biochemical and Biophysical Research Communications, 2005, 329, 1225-1233.	2.1	27
41	Lung malignancies after Hodgkin lymphoma: disease characteristics, detection methods and clinical outcome. Annals of Oncology, 2012, 23, 1813-1818.	1.2	26
42	The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. Oncologist, 2020, 25, 598-608.	3.7	26
43	Everolimus in Anaplastic Thyroid Cancer: A Case Series. Frontiers in Oncology, 2019, 9, 106.	2.8	25
44	Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 102, 137-145.	0.8	24
45	Immune effects of targeted radiation therapy for cancer. Discovery Medicine, 2015, 19, 219-28.	0.5	24
46	Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomarkers, 2017, 19, 129-136.	1.7	22
47	Denaturation-Enhanced Droplet Digital PCR for Liquid Biopsies. Clinical Chemistry, 2018, 64, 1762-1771.	3.2	21
48	Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. Oral Oncology, 2020, 106, 104690.	1.5	21
49	A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer. Clinical Cancer Research, 2013, 19, 1612-1619.	7.0	20
50	Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. Oral Oncology, 2016, 61, 19-26.	1.5	20
51	Shortâ€term mortality risks among patients with oropharynx cancer by human papillomavirus status. Cancer, 2020, 126, 1424-1433.	4.1	20
52	Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancerâ€“A Perspective on Future Trial Designs. Clinical Cancer Research, 2019, 25, 7281-7286.	7.0	19
53	Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for nonâ€“small cell lung cancer and melanoma brain metastases. Cancer, 2020, 126, 5274-5282.	4.1	19
54	Anti-angiogenesis immunotherapy. Hum Vaccin, 2011, 7, 976-981.	2.4	17

#	Article	IF	Citations
55	Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. , 2016, 4, 32.		17
56	Abbreviated course of radiotherapy (RT) for breast cancer. Breast, 2011, 20, S116-S127.	2.2	16
57	Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncology, 2020, 105, 104676.	1.5	16
58	Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. Oral Oncology, 2018, 85, 29-34.	1.5	15
59	Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib--a case report. Anticancer Research, 2012, 32, 1743-6.	1.1	15
60	Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase IIIÂstudy design. Future Oncology, 2022, 18, 1669-1678.	2.4	15
61	Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. , 2022, 10, e004034.		14
62	Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: A dual-center retrospective study. Journal of the American Academy of Dermatology, 2022, 87, 87-94.	1.2	14
63	PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S139-S146.	2.8	11
64	Populationâ€based validation of the recursive partitioning analysisâ€“based staging system for oropharyngeal cancer. Head and Neck, 2016, 38, 1530-1538.	2.0	9
65	Radiation dose and checkpoint blockade immunotherapy: unanswered questions. Lancet Oncology, The, 2016, 17, e3-e4.	10.7	9
66	Prospective analysis of radiation oncology image and planâ€driven peer review for head and neck cancer. Head and Neck, 2017, 39, 1603-1608.	2.0	9
67	Funding Support and Principal Investigator Leadership of Oncology Clinical Trials Using Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 34-43.	0.8	9
68	Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy. Frontiers in Oncology, 2019, 9, 199.	2.8	9
69	Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade. JCO Precision Oncology, 2020, 4, 1196-1206.	3.0	9
70	NUT Carcinoma of the Thyroid: An Unusual Case with a Complete Response to Treatment. Clinical Thyroidology, 2021, 33, 38-47.	0.1	9
71	PET/CT of Cancer Patients: Part 2, Deformable Registration Imaging Before and After Chemotherapy for Radiation Treatment Planning in Head and Neck Cancer. American Journal of Roentgenology, 2012, 199, 968-974.	2.2	8
72	Ensuring Head and Neck Oncology Patients Receive Recommended Pretreatment Dental Evaluations. Journal of Oncology Practice, 2015, 11, 151-154.	2.5	8

#	Article	IF	Citations
73	We Are All Connected: Modeling the Tumor-Immune Ecosystem. Trends in Cancer, 2018, 4, 655-657.	7.4	8
74	A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2019, 105, 132-139.	0.8	8
75	IMRTâ€based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. Head and Neck, 2019, 41, 959-966.	2.0	8
76	Keynote 48: Is it really for everyone?. Oral Oncology, 2020, 105, 104762.	1.5	8
77	Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. Oral Oncology, 2021, 112, 105087.	1.5	8
78	Prospective Clinical Investigation of the Efficacy of Combination Radiation Therapy With Immune Checkpoint Inhibition. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1165-1175.	0.8	8
79	Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.. Journal of Clinical Oncology, 2021, 39, 6053-6053.	1.6	7
80	Radiation Therapy and Immune Modulation. Hematology/Oncology Clinics of North America, 2019, 33, 233-248.	2.2	6
81	Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes. Head and Neck, 2022, 44, 722-734.	2.0	6
82	The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 243-247.	1.3	5
83	Radiation-Induced Hypothyroidism in Patients with Oropharyngeal Cancer Treated with IMRT: Independent and External Validation of Five Normal Tissue Complication Probability Models. Cancers, 2020, 12, 2716.	3.7	5
84	Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy. World Neurosurgery, 2020, 139, 226-231.	1.3	5
85	Potential Role of the Quality Assurance Review Center Platform in Global Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2017, 99, 956-962.	0.8	4
86	Outcomes following radiation for cutaneous squamous cell carcinoma of the head and neck: Associations between immune suppression and recurrence. Head and Neck, 2019, 41, 2111-2115.	2.0	4
87	The effects of releasing early results from ongoing clinical trials. Nature Communications, 2021, 12, 801.	12.8	4
88	Long-term Overall Survival and Predictors in Antiâ€“PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. Journal of Immunotherapy, 2021, 44, 307-318.	2.4	4
89	Technical note: Toward implementation of MRâ€guided radiation therapy for laryngeal cancer with healthy volunteer imaging and a custom MRâ€CT larynx phantom. Medical Physics, 2022, 49, 1814-1821.	3.0	4
90	Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd couple. BJR|case Reports, 2016, 2, 20150271.	0.2	3

#	Article	IF	Citations
91	Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. Head and Neck, 2020, 42, 3670-3677.	2.0	3
92	Association between treatment center experience and survival after diagnosis of stage I to III Merkel cell carcinoma treated with surgery with or without postoperative radiation therapy. Journal of the American Academy of Dermatology, 2021, 84, 875-877.	1.2	3
93	Personalized Radiation Attenuating Materials for Gastrointestinal Mucosal Protection. Advanced Science, 2021, 8, 2100510.	11.2	3
94	Dosimetric Modeling of Lymphopenia in Patients With Metastatic Cancer Receiving Palliative Radiation and PD-1 Immune Checkpoint Inhibitors. Advances in Radiation Oncology, 2022, 7, 100880.	1.2	3
95	Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers. Head and Neck, 2022, , .	2.0	3
96	Use of Fluoro-[¹⁸F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. JAMA Otolaryngology - Head and Neck Surgery, 2022, 148, 268.	2.2	3
97	Immunotherapy and Radiation. Hematology/Oncology Clinics of North America, 2019, 33, 1057-1069.	2.2	2
98	Head and Neck Cancer Clinical Research on ClinicalTrials.gov: An Opportunity for Radiation Oncologists. Advances in Radiation Oncology, 2021, 6, 100608.	1.2	2
99	Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumabâ€"Reply. JAMA Oncology, 2021, 7, 309.	7.1	1
100	Imaging features, therapies, and outcomes of fibrosing inflammatory pseudotumor of the nasopharynx: A systematic review. Journal of Neuroimaging, 2022, 32, 223-229.	2.0	1
101	Reply to â€œKeynote 48: Is it really for everyone?â€• Oral Oncology, 2021, 115, 105108.	1.5	0
102	Radiosensitizers in the Era of Immuno-Oncology. Cancer Drug Discovery and Development, 2020, , 339-360.	0.4	0
103	Unusual presentation of HPV-positive squamous cell carcinoma of the nasolacrimal duct as carcinoma of unknown primary. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2022, 43, 103457.	1.3	0